Zealthy and iV.im are two telehealth platforms serving GLP-1 seekers, each with different screening philosophies and biomarker integration. Understanding their eligibility assessment and genetic considerations can help you choose an approach aligned with your wellness goals and medical history.

Zealthy and Ro represent two distinct telehealth models for GLP-1 access, each with different provider credentials, medication sourcing, and cost structures.

This review focuses on tirzepatide as offered through Zealthy: why the dual GIP/GLP-1 mechanism sets it apart, how branded tirzepatide differs from compounded, the way the program dispenses it, what it costs, and the genetic context beneath any tirzepatide response.

This review narrows in on semaglutide as prescribed through Zealthy: what the molecule does, how branded semaglutide differs from compounded semaglutide, the way a prescription moves from intake to pharmacy, and the genetic context that shapes semaglutide biology before any dose.

This overview looks at Zealthy as a GLP-1 telehealth program end to end: what the offering includes, how eligibility and intake work, which compounds are in play, how pricing behaves across the market, and the genetic variable that sits upstream of every prescription.

This editorial review examines Zealthy's weight-loss program as of April 2026 — how the subscription telehealth model works, how prescriptions are routed to retail or compounding pharmacies, what drives the monthly cost, and the inherited genetic factors no intake form captures.